Tourmaline Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 42.12 million compared to USD 19.7 million a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.28 USD | +1.63% |
|
-0.93% | -40.89% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.89% | 386M | |
+15.61% | 122B | |
+19.25% | 113B | |
+3.61% | 22.66B | |
-17.79% | 21.34B | |
-41.55% | 16.92B | |
-14.77% | 16.68B | |
-16.03% | 16.61B | |
+2.82% | 13.62B | |
+22.57% | 11.04B |
- Stock Market
- Equities
- TRML Stock
- News Tourmaline Bio, Inc.
- Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023